Randomized phase 2 trial of Intravenous Gamma Globulin (IVIG) for the treatment of acute vaso-occlusive crisis in patients with sickle cell disease: Lessons learned from the midpoint analysis

Deepa Manwani, Chunliang Xu, Sung Kyun Lee, George Amatuni, Hillel W. Cohen, Veronica Carullo, Kerry Morrone, Jennifer Davila, Patricia Ann Shi, Karen Ireland, Janine Keenan, Paul S. Frenette

Research output: Contribution to journalArticle

Abstract

Sickle Cell Disease (SCD) is a chronic hemolytic disorder associated with frequent pain episodes, end organ damage and a shortened lifespan. Currently there exist no disease specific targeted therapies for the treatment of acute vaso-occlusive crisis (VOC) and management with analgesics and hydration is purely supportive. Improvement in understanding of disease pathophysiology has resulted in a great interest in disease modifying novel therapies and many are being evaluated in clinical trials. Here we report the results from the pre-specified mid-point analysis of the Phase 2 study of Intravenous Gamma Globulin (IVIG) for the treatment of acute VOC in patients with SCD and lessons learned.

Original languageEnglish (US)
Article number102481
JournalComplementary Therapies in Medicine
Volume52
DOIs
StatePublished - Aug 2020

Keywords

  • IVIG
  • Immune globulin
  • Sickle

ASJC Scopus subject areas

  • Complementary and Manual Therapy
  • Complementary and alternative medicine
  • Advanced and Specialized Nursing

Fingerprint Dive into the research topics of 'Randomized phase 2 trial of Intravenous Gamma Globulin (IVIG) for the treatment of acute vaso-occlusive crisis in patients with sickle cell disease: Lessons learned from the midpoint analysis'. Together they form a unique fingerprint.

  • Cite this